News

News and Press Releases
About the CF Foundation | CFTR Modulators FDA Approves Ivacaftor for People with R117H Mutation of Cystic Fibrosis

The U.S. Food and Drug Administration (FDA) announced today that it has approved the use of ivacaftor (Kalydeco™) to treat people with cystic fibrosis ages 6 and older who have the R117H mutation.

| 2 min read
About the CF Foundation | CFTR Modulators Cystic Fibrosis Foundation Therapeutics Announces $15 Million Research Project for Development of Novel CF Treatment

Cystic Fibrosis Foundation Therapeutics Inc., the nonprofit affiliate of the Cystic Fibrosis Foundation, announced today a $15 million research agreement with biopharmaceutical company Shire plc to support the development of a new cystic fibrosis treatment targeting the underlying cause of the disease.

| 2 min read
About the CF Foundation | CFTR Modulators | Clinical Trials Letter to the Community on Exciting Vertex Clinical Trials Results

This morning, Vertex Pharmaceuticals announced the results from the Phase 3 clinical trials of ivacaftor (Kalydeco™) and lumacaftor (VX-809) in people with two copies of the F508del mutation.

| 4 min read
About the CF Foundation | CFTR Modulators Cystic Fibrosis Foundation Therapeutics Extends Drug Development Collaboration with Proteostasis Therapeutics

Cystic Fibrosis Foundation Therapeutics, Inc. (CFFT), an affiliate of the Cystic Fibrosis Foundation, announced it will extend funding for continued collaboration with Proteostasis Therapeutics, Inc., for the development of new therapies to treat the most common CF mutation, Delta F508.

| 2 min read
About the CF Foundation | CFTR Modulators FDA Approves Expanded Use of Kalydeco™ for Eight Additional Mutations that Cause CF

The U.S. Food and Drug Administration announced today it has approved Kalydeco™ to treat people ages 6 and older who have one of eight additional cystic fibrosis mutations.

| 3 min read